title: Genetic polymorphisms potentially associated with response to metformin in postmenopausal diabetics suffering and not suffering with cancer.
abstract: Metformin is a well-known antidiabetic medication, which, besides diabetes, may be involved into modulation of other age-related pathologies, including cancer. The study concerns 12 gene polymorphisms divided into 2 groups consisting of 6 genes each. The first group was composed from so-called "standard" (S) polymorphisms, for which the connection with metabolic response to metformin is already established. The second group included polymorphisms of genes encoding proteins possibly connected with diabetes mellitus type 2 (DM2), impaired glucose tolerance or cancer and entitled here as "associated" (A). A total of 156 postmenopausal women (average age 60.7 ± 0.7) were included, 37 of them healthy, 64 with type DM2 and concurrent treatment-naïve cancer (mostly breast, endometrial or colorectal cancer), 32 with DM2 without cancer, and 23 with treatment-naïve cancer and normal glucose tolerance. The leading metformin response S-marker in combined group of DM2 patients was the CC variant of OCT1-R61C polymorphism of organic cation transporter protein 1 gene. In cancer patients without DM2, this position belonged to AC and AA genotypes of OCT1_rs622342 polymorphism. Among the A-polymorphisms, GA variant of sex hormone-binding globulin gene SHBG_D356N was less frequently observed in DM2 patients with or without cancer. Besides, in diabetics, the same polymorphic variant of SHBG as well as GC genotype of oxidized lipoprotein receptor OLR1_G501C and GG genotype of locus rs11065987 near BRAP gene were carried rather often in combination with "metformin-positive" variant of OCT1_R61C. In addition, carriers of OCT1_R61C and OCT1_rs622342 polymorphisms with potentially positive reaction to metformin had higher insulin resistance score (HOMA-IR) values. Received data lead to the conclusion that postmenopausal diabetics, both with and without cancer, differ in genetic stigmata of potential response to metformin less than they differ from cancer patients without DM2. As genetic polymorphisms associated with metabolic and anticancer metformin (and, possibly, phenformin) effects may be different, this subject requires further investigation.
authors.affiliation: Laboratory of Oncoendocrinology; N.N.Petrov Research Institute of Oncology; St.Petersburg, Russia.
authors.forename: Lev M
authors.initials: LM
authors.lastname: Berstein
authors.forename: Aglaya G
authors.initials: AG
authors.lastname: Iyevleva
authors.forename: Dmitry
authors.initials: D
authors.lastname: Vasilyev
authors.forename: Tatyana E
authors.initials: TE
authors.lastname: Poroshina
authors.forename: Evgeny N
authors.initials: EN
authors.lastname: Imyanitov
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000483:Alleles; D003924:Diabetes Mellitus, Type 2 / Q000150:complications / Q000188:drug therapy / Q000235:genetics; D004958:Estradiol / Q000097:blood; D005260:Female; D005838:Genotype; D006801:Humans; D007004:Hypoglycemic Agents / Q000627:therapeutic use*; D008687:Metformin / Q000627:therapeutic use*; D008875:Middle Aged; D009369:Neoplasms / Q000150:complications*; D027702:Organic Cation Transporter 1 / Q000235:genetics; D011110:Polymorphism, Genetic; D017698:Postmenopause; D011956:Receptors, Cell Surface / Q000235:genetics; D051127:Scavenger Receptors, Class E / Q000235:genetics
chemical_list: D007004:Hypoglycemic Agents; C495137:OLR1 protein, human; D027702:Organic Cation Transporter 1; D011956:Receptors, Cell Surface; D051127:Scavenger Receptors, Class E; C063572:sex hormone-binding globulin receptor; D004958:Estradiol; D008687:Metformin
keywords: cancer; diabetes; metformin; pharmacogenetics; polymorphisms; postmenopausal females